Back to Journals » ClinicoEconomics and Outcomes Research » Volume 11

North American cost analysis of brand name versus generic drugs for the treatment of glaucoma

Authors Malvankar-Mehta MS, Feng L, Hutnik CML

Received 22 June 2018

Accepted for publication 5 July 2019

Published 16 December 2019 Volume 2019:11 Pages 789—798

DOI https://doi.org/10.2147/CEOR.S156558

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Xing Lin Feng


Monali S Malvankar-Mehta,1,2 Lucy Feng,3 Cindy ML Hutnik1,4

1Department of Ophthalmology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario N6A 4V2, Canada; 2Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario N6A 5C1, Canada; 3School of Pharmacy, University of Waterloo, Kitchener, Ontario N2G 2B2, Canada; 4Department of Pathology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON N6A 5C1, Canada

Correspondence: Monali S Malvankar-Mehta
Department of Ophthalmology, St. Joseph’s Hospital, 268 Grosvenor Street, London, Ontario N6A 4V2, Canada
Tel +1 519 685 8500 Ext 61288
Fax +1 519 661 3766
Email Monali.Malvankar@schulich.uwo.ca

Background: According to the World Health Organization, glaucoma is a leading cause of irreversible blindness worldwide. By 2020, 80 million people will be affected by glaucoma in the world, which represents a significant financial burden to society. Glaucoma medications alone make up 38–52% of the total direct cost. The purpose of this research is to conduct a cost-minimization analysis to evaluate brand-name medications versus generic medications for treating glaucoma patients.
Methods: The per-bottle cost (in Canadian dollars) of brand-name drugs for glaucoma was obtained from the wholesaler, McKesson Canada, and, for generic drugs, from the Ontario Drug Benefit (ODB) Formulary. Further, a wastage adjustment fee, a pharmacy mark-up, and an ODB dispensing fee ($CAD) was added to the cost of both brand and generic. Previously published frequencies of medication prescription were utilized to calculate the average annual cost for each class of brand and generic. For each medication class and for mono-, bi-, and tri-drug therapy, the cost differential between brands and generics over a six-year period was computed and analyzed from third-party payer perspective.
Results: In descending order, the average annual government-funded health care system costs were: combination drugs such as Cosopt® ($748.23) were the most expensive, followed by prostaglandin analogs ($246.36), carbonic anhydrase inhibitors (CAIs) ($45.04), α-agonist ($30.34), β-blockers ($29.29), and cholinergic agonists ($16.51). Brand-name mono-drugs are 34% more expensive compared to generics. Brand-generic percentage cost differential for various medication classes over a six-year period was the highest for prostaglandin analogous (44%), followed by β-blockers (35%), α-agonist (31%), cholinergic agonists (22%), combination drugs (10%), and CAIs (1%).
Conclusion: Brand-name drugs are relatively more expensive than their generic counterparts, with variable cost differentials depending on drug class.

Keywords: glaucoma, open-angle, cost analysis, generic drugs, branded drugs
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]